Tuesday, 01 October 2019 08:00

Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin _the Spanish population of the MabRella study

Results of a safety study examining the change from intravenous to subcutaneous rituximab during first line treatment of patients with non?Hodgkin lymphomas.

Additional Info

  • Publication: British Journal of Haematology
  • Sub Type: Diffuse Large B-cell (DLBCL), Follicular (FL)
  • Country: Spain


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 02/19/19. Copyright © 2018 Lymphoma Coalition. All rights reserved.